Table 1.

Patient baseline characteristics

Patients (N = 41)
Median age (range), y54 (22–77)
Male/female (n)20/21
ECOG performance statusa, n
 021
 119
 20
Primary tumor type, n (%)
 Melanoma6 (15)
 Breast5 (12)
 Kidney4 (10)
 Ovarian4 (10)
 Liposarcoma4 (10)
 Colon3 (7)
 Other15 (37)
Prior therapy, n (%)
 Any41 (100)
 Chemotherapy34 (83)
 1–2 regimens21 (51)
 3 regimens12 (29)
 >3 regimensb1 (2)
Hormonal4 (10)
Immunotherapy/biologic7 (17)
Radiotherapy17 (42)
Surgery37 (90)
  • aECOG PS score not available for one patient.

  • bOne patient who had received more than 3 prior cytotoxic chemotherapy regimens was enrolled into the study. Although the relevant inclusion criterion was such that patients were eligible with up to 3 prior cytotoxic chemotherapy regimens, this patient was enrolled with the agreement of the study sponsor and does not, therefore, represent a protocol deviation. The inclusion of this patient in the analysis populations did not affect the conduct or conclusions of the study.